Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment

Bausch Health Companies Inc. (NYSE:BhcHe is one of Canadian stocks are the most appreciated to buy now. On July 29, Bausch health companies announced a final agreement to obtain Durect Corporation (NASDAQ:Drx). The value of the acquisition is about 63 million dollars in advance, with the possibility of obtaining sales payments of an additional $ 350 million sales, and it will be a deal from all inscriptions.

Bausch Health is primarily acquired for its leading origins, which are called Larsucosterol. This new therapeutic molecule is a genetic average that gave the FDA to treat alcohol/AH, a life -threatening form of alcohol -related liver disease.

Close to the pillow in a pharmacy, the company is high quality medications.

AH is characterized by severe hepatitis and its necrosis and is about 164,000 hospital acceptance in the United States in 2021. There are currently no food and drug management treatments (FDA or European drugs/EMA remedies for this case. The acquisition of larsucosterol enhances the commitment of Bausch Health to the liver. To use its expertise to enhance Larsucosterol through its plan 3 program.

Bausch Health Companies Inc. (NYSE: BHC) is a specialized company for pharmaceutical and medical devices that develop, manufacture and market products in digestive system diseases, liver science, neuroscience, skin diseases, general medications, OTC products, nerve and eye health devices.

Durect Corporation (NASDAQ: DRRX) is a late vital pharmaceutical pharmaceutical company that develops genetic treatments that target unregular DNA to transform the treatment of dangerous life -threatening conditions, such as acute organ injury.

While we acknowledge the BHC capabilities as an investment, we believe that some artificial intelligence shares provide greater potential in the upward trend and carry less negative risks. If you are looking for a stock of artificial intelligence with less than very apprecia The best inventory of artificial intelligence in the short term.

Read the following: 30 stocks must double in 3 years and 11 stocks of hidden artificial intelligence for purchase now.

Detection: Nothing. This article was originally published in A monkey from the inside.